Ducon rights issue: BSE-NSE nod for ₹25 crore in 2026

What the exchange approvals mean

Ducon Infratechnologies Limited has received in-principle approvals from both BSE Limited and the National Stock Exchange of India Limited (NSE) for its proposed rights issue of equity shares. The approval letters are dated August 6, 2026, and the company communicated the development on August 7, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approvals clear an important regulatory step before the company can announce the rights issue schedule and open subscriptions for eligible shareholders. The rights issue is proposed to be up to ₹25 crore.

The rights issue is planned as an issuance of fully paid-up equity shares on a rights basis to existing shareholders. The face value is Re 1 per equity share, as referenced in the exchange communication. The company is listed under Symbol: DUCON, Scrip Code: 534674, ISIN: INE741L01018.

Rights issue plan approved earlier by the board

The company’s board had earlier approved the rights issue to raise up to ₹25 crore. The approval is referenced as having taken place on June 13, 2026, with a separate communication also describing a board-approved rights issue announcement around mid-June 2026. The stated purpose of the fundraising includes funding working capital needs and repaying promoter loans of ₹9.52 crore.

The company has also disclosed a more granular intended use of proceeds in its rights issue communication. It indicated that proceeds would be used to adjust unsecured loans from promoter Arun Govil up to ₹9.52 crore, provide ₹7.36 crore towards incremental working capital requirements, and allocate ₹5.62 crore towards general corporate purposes. The company has also indicated that net proceeds are estimated at ₹22.50 crore.

Board meeting on August 19 to finalise key terms

Ducon has scheduled a board meeting for Wednesday, August 19, 2026 at 05:30 P.M. The meeting is to be held at the company’s registered office at Ducon House, Plot No. A/4, Road No. 1, MIDC, Wagle Industrial Estate, Thane, Maharashtra, India – 400604.

As per the board agenda disclosed, directors will discuss, consider and approve the brief terms of the rights issue. This includes the equity shares to be offered through the issue, issue price per equity share, rights entitlement ratio, terms of payment, and the record date to determine shareholder eligibility. The company has noted that additional items may be taken up with the permission of the chairman.

Trading window closure tied to the board meeting

The company has also stated that the trading window for dealing in its equity shares will remain closed for Designated Persons and their immediate relatives. This closure is pursuant to Clause 4 of Schedule B of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s internal code on insider trading prevention.

The trading window is to remain closed until 48 hours after the conclusion of the board meeting. Such closures are commonly used to manage information sensitivity around decisions such as pricing, entitlement ratios, and record dates.

Exchange letters and conditions to be complied with

The BSE in-principle approval letter is referenced as LOO/RIGHT /RB/FIP /626/2026-27 dated August 6, 2026. The NSE in-principle approval letter is referenced as NSE/LIST/55767 dated August 6, 2026. NSE’s approval pertains to the proposed rights issue of fully paid-up equity shares of Re 1 each, with an issue size of up to ₹25 crore.

The approvals are subject to the company meeting various conditions. These include filing the listing application and obtaining statutory approvals from authorities such as SEBI, RBI, and MCA, as applicable. The company will also need to complete operational prerequisites referenced in the communication, including setting a record date, disclosing issue price, and completing depository arrangements with NSDL and CDSL.

How the proceeds are expected to be used

Ducon has described the rights issue as a step to strengthen its balance sheet and fund operational requirements. A key element is repayment or adjustment of unsecured promoter loans, along with incremental working capital funding and general corporate purposes. The company has also indicated that promoter Arun Govil intends to subscribe fully.

The planned utilisation and the net proceeds estimate provide investors an indication of how much of the gross ₹25 crore issue size may translate into deployable funds after issue-related expenses. However, the final structure will depend on the terms approved by the board and the final Letter of Offer.

Key facts at a glance

Proposed fund allocation disclosed by the company

Market impact and what shareholders should track next

The in-principle approvals allow Ducon to move towards finalising the rights issue process, but the investment decision for shareholders will hinge on the terms. The most important near-term disclosures are the issue price, the rights entitlement ratio, the record date, and the payment schedule. These will determine the effective cost for existing shareholders and the quantum they are eligible to subscribe.

From a balance-sheet perspective, the disclosed plan to adjust or repay ₹9.52 crore of promoter loans is a central element of the fundraising objective, alongside funding incremental working capital. The company has also stated that detailed terms and conditions, including the record date and application process, will be specified in the Letter of Offer issued in due course.

Conclusion

Ducon’s receipt of in-principle approvals from BSE and NSE dated August 6, 2026 positions the company to proceed with its proposed ₹25 crore rights issue. The next key milestone is the board meeting scheduled for August 19, 2026, where pricing, entitlement ratio, payment terms and the record date are expected to be considered and approved, ahead of the Letter of Offer and subscription timeline.